SOS1/EGFR-IN-1

SOS1/EGFR-IN-1 (compound SE-9) is a dual-target inhibitor for the prostate cancer. SOS1/EGFR-IN-1 inhibits effectively SOS1 (IC50=42.13±1.55 nM) and EGFR (IC50=1.01±0.04 nM) by inhibiting their downstream effector molecules. SOS1/EGFR-IN-1 induces apoptosis and G1 phase cell cycle arrest, reducing angiogenesis and migration. SOS1/EGFR-IN-1 shows significant antitumor effects in prostate cancer cells PC-3 (IC50=0.45±0.03 μM) [1].

Product Specifications

CAS Number

[2956724-20-0]

UNSPSC

12352005

Target

EGFR; Ras; SOS1

Type

Reference compound

Related Pathways

GPCR/G Protein; JAK/STAT Signaling; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/sos1-egfr-in-1.html

Purity

99.54

Solubility

DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

FC1=CC([C@@H](C)NC2=C3C=C(OC4CCOCC4)C(OC)=CC3=NC=N2)=CC=C1

Molecular Formula

C22H24FN3O3

Molecular Weight

397.44

References & Citations

[1]Zheng L, et al. Discovery of a Potent Dual Son of Sevenless 1 (SOS1) and Epidermal Growth Factor Receptor (EGFR) Inhibitor for the Treatment of Prostate Cancer[J]. Journal of Medicinal Chemistry, 2024.